English 
Metastatic Renal cell carcinoma (mRCC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
Currently, tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies are widely used in first- and second-line treatments for mRCC. Despite the current treatments, there remains the unmet need for early diagnosis and treatment options. Emerging drugs in development like Dovitinib (Allarity Therapeutics) and Savolitinib/ AZD6094 (Astrazeneca), and others will expand the first-line and second-line settings for patients with mRCC and likely to address the current unmet needs for the treatment of mRCC. The upcoming treatment options for mRCC can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
Description
Renal cell carcinoma (RCC) is a type of kidney cancer which originates within the renal cortex and are responsible for 80% to 85% of all primary renal neoplasms. It is the most common form of kidney cancer found in adults. RCC metastasizes in approximately 20–30% of the cases. According to National Cancer Institute, Metastatic renal cell carcinoma (mRCC) is a heterogeneous disease with wide variations in its clinical presentation, natural history, and response to therapy. The most common sites for metastases of RCC are the lungs, bones, liver, and brain. The recurrence of RCC after initial care is relatively high and certain subtypes such as clear cell RCC are more likely to metastasize. A more recent discovery with new immune checkpoint inhibitors heralded a further paradigm shift from TKI monotherapy to immunotherapy-based combinations.
Metastatic Renal cell carcinoma (mRCC)– Epidemiology
Renal Cell Carcinoma diagnosis majorly depends on abdominal imaging or upon presentation of invasive disease at common metastatic sites, such as the lung, bone, and liver. Computerized tomography (CT) remains the gold standard for the diagnosis of Renal cell carcinoma (RCC). Abdominal ultrasonography (USG), MRI, blood test and urine analysis are common diagnostic tools being used for the diagnosis. Core biopsy and pathological examination are performed to confirm the diagnosis in case of renal cell carcinoma identified in both kidney and at distant metastatic sites. More than 50% of patients with renal cell carcinoma are asymptomatic and diagnosed incidentally during thoracoabdominal imaging ordered for unrelated issues.
RCC occurs mostly in adults and often in men ages 50 to 70. The incidence of RCC varies with the highest rates observed in the North America. In the United States, there are approximately 63,000 new cases and almost 14,000 deaths each year. In the United States, incidence rates of RCC have been on the rise through the mid-2000s.
Metastatic Renal cell carcinoma (mRCC)– Current Market Size & Forecast Trends
The renal cell carcinoma market has witnessed a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer / Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivoplus Cabometyx (Exelixis / Ipsen) and axitinib plus pembrolizumab combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period.
Additionally, the anticipated entry of other agents such as bempegaldesleukin (NektarTherapeutics) and belzutifan (Merck & Co.) will further diversify treatment options and create a highly competitive and dynamic market.The current treatment market has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has diversified treatment options and the treatment landscape for renal cell carcinoma market is rapidly moving toward combination combinatorial approaches.
The introduction of diagnostic companions could offer the possibility of providing better outcomes and reducing the cost-burden of patients that are less likely to respond to the therapy. Metastatic Renal cell Carcinoma (mRCC) is expected to see a high growth during our forecast period. The market in the G7 countries is expected to reach more than USD 8 billion in 2032 with a CAGR of 7.5%. Primary drivers of this growth will be the uptake of the emerging drugs i.e., Belzutifan (Merck/Peloton Therapeutics), Bempegaldesleukin (Bristol-Myers Squibb/Nektar Therapeutics), and others.
Report Highlights
- Metastatic Renal cell carcinoma (mRCC)– Current Market Trends
- Metastatic Renal cell carcinoma (mRCC)– Current & Forecasted Cases across the G7 Countries
- Metastatic Renal cell carcinoma (mRCC)– Market Opportunities and Sales Potential for Agents
- Metastatic Renal cell carcinoma (mRCC)– Patient-based Market Forecast to 2032
- Metastatic Renal cell carcinoma (mRCC)– Untapped Business Opportunities
- Metastatic Renal cell carcinoma (mRCC)– Product Positioning Vis-a-vis Competitors’ Products
- Metastatic Renal cell carcinoma (mRCC)– KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- Executive Summary
- Key Findings
- Metastatic Renal cell carcinoma (mRCC) Disease Background
- Renal Cell Carcinoma (RCC) Definition
- Symptoms and Causes
- Pathogenesis
- Stages
- Classification
- Metastatic Renal cell carcinoma (mRCC) Diagnosis
- Diagnosis & Diagnostic Guidelines
- Biomarkers
- Challenges
- Epidemiology and Patient Populations
- Key Findings
- Methods and data Sources
- Country Specific Incident Populations with Renal Cell Carcinoma (RCC) (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Incident Population with Metastatic Renal Cell Carcinoma (mRCC)
- Country Specific Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- Key Sources for Metastatic Renal cell carcinoma (mRCC) Epidemiology and Model Parameters
- United States
- United States Incident Populations with Renal Cell Carcinoma (RCC)
- United States Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- United States Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- Germany
- Germany Incident Populations with Renal Cell Carcinoma (RCC)
- Germany Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- Germany Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- France
- France Incident Populations with Renal Cell Carcinoma (RCC)
- France Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- France Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- Italy
- Italy Incident Populations with Renal Cell Carcinoma (RCC)
- Italy Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- Italy Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- United States
-
-
- Spain
- Spain Incident Populations with Renal Cell Carcinoma (RCC)
- Spain Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- Spain Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- United Kingdom
- United Kingdom Incident Populations with Renal Cell Carcinoma (RCC)
- United Kingdom Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- United Kingdom Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- Japan
- Japan Incident Populations with Renal Cell Carcinoma (RCC)
- Japan Incident Populations with Metastatic Renal Cell Carcinoma (mRCC)
- Japan Treated Cases of Metastatic Renal Cell Carcinoma (mRCC) by Line of Therapies
- Spain
-
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- NCCN Treatment Guidelines
- First- Line Therapy for Clear Cell Histology as per the NCCN Guidelines
- Subsequent Therapy for Clear Cell Histology
- Systemic Therapy for Non- Clear Cell Histology
- KOLs Opinion on Current Treatment Option
- Metastatic Renal cell carcinoma (mRCC)- Treatment Studies
- Treatment patterns of Metastatic Renal cell carcinoma by Line of Therapy: United States
- Trends in 1 L Treatment Initiation for Metastatic Renal cell carcinoma: United States
- Treatment patterns of Metastatic Renal cell carcinoma by Line of Therapy: United Kingdom
- Treatment Patterns in Patients with Metastatic Renal cell carcinoma: Germany
- Treatment Costs of Patients with Metastatic Renal cell carcinoma: Italy
- Treatment Costs of Patients with Metastatic Renal cell carcinoma : France
- In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma: France
- Treatment Patterns in Patients with Metastatic Renal cell carcinoma: Japan
- Unmet Needs
- Metastatic Renal cell carcinoma (mRCC)- Marketed Drug Chapters
- Treatment Landscape of mRCC
- Key trials for Renal Cell carcinoma
- Clinical data comparisons in 1L and 2L settings
- RCC treatment rankings based on efficacy and safety
- Product Profile
- Clinical Trial Analysis
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Metastatic Renal cell carcinoma (mRCC)
- Product Analysis
- Phase III
- Belzutifan (Merck/Peloton Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Dovitinib (Allarity Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Savolitinib (Astrazeneca)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Bempegaldesleukin (Bristol-Myers Squibb/Nektar Therapeutics)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Atezolizumab (Hoffmann-La Roche/Exelixis)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Abexinostat (Xynomic Pharmaceuticals)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Belzutifan (Merck/Peloton Therapeutics)
- Phase II
- PT2385 (Kolon Life Science)
- Product Profile
- Clinical Development
- Sitravatinib (Mirati Therapeutics)
- Product Profile
- Clinical Development
- Crizotinib (Pfizer)
- Product Profile
- Clinical Development
- TLX250 (Telix Pharmaceuticals)
- Product Profile
- Clinical Development
- PT2385 (Kolon Life Science)
-
-
-
- ALT-803 (NantWorks/ImmunityBio)
- Product Profile
- Clinical Development
- ALT-803 (NantWorks/ImmunityBio)
- Phase I/II
- AVB-500 (Aravive)
- Product Profile
- Clinical Development
- AVB-500 (Aravive)
-
-
- Metastatic Renal cell carcinoma (mRCC)- Pricing & Reimbursement
- Future Treatment Paradigm
- Metastatic Renal cell carcinoma (mRCC) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
- Sales of Drugs to Treat Metastatic Renal cell carcinoma (mRCC) in the Major Pharmaceutical Markets, 2018-2032
- Patient Share of Metastatic Renal cell carcinoma (mRCC) Therapies and by Drug
- Market Forecast by Country
- United States
- United States Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- United States Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- Germany Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- France
- France Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- France Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- Italy Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- Spain Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- United Kingdom Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Metastatic Renal cell carcinoma (mRCC) 2022-2032 (USD Million)
- Japan Market for Metastatic Renal cell carcinoma (mRCC) by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Metastatic Renal cell carcinoma (mRCC)?
- What Factors Are Constraining the Market for Metastatic Renal cell carcinoma (mRCC)?
- Appendix
Sample Enquiry
Related products
-
HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
$6,989.00 – $20,967.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Acute Myeloid Leukemia (AML) –Tumour Slide Deck 2023
$11,800.00 – $20,000.00
$5,900.00 – $10,000.00Select optionsThe research study conducted by Mellalta Meets provides insights into the AML market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the AML population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of AML treatment.